{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T13:19:12Z","timestamp":1784207952422,"version":"3.55.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T00:00:00Z","timestamp":1717977600000},"content-version":"am","delay-in-days":222,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100020549","name":"Centre L\u00e9on B\u00e9rard","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020549","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010463","name":"Institut Curie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010463","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013944","name":"Institut de Canc\u00e9rologie de Lorraine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013944","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine and Research"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.resmer.2023.101012","type":"journal-article","created":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T02:11:18Z","timestamp":1679883078000},"page":"101012","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Treatment patterns and clinical outcomes of extensive stage small cell lung cancer (SCLC) in the real-world evidence ESME cohort before the era of immunotherapy"],"prefix":"10.1016","volume":"84","author":[{"given":"Clarisse Audigier","family":"Valette","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Filleron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Debieuvre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Lena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurice","family":"P\u00e9rol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Chouaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga\u00ebtane","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Quantin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Girard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.resmer.2023.101012_bib0001","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/nrc.2017.87","article-title":"Small-cell lung cancer: what we know, what we need to know and the path forward","volume":"17","author":"Gazdar","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.resmer.2023.101012_bib0002","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jtho.2015.10.008","article-title":"The international association for the study of lung cancer lung cancer staging project: proposals for the revision of the clinical and pathologic staging of small cell lung cancer in the forthcoming eighth edition of the TNM classification for lung cancer","volume":"11","author":"Nicholson","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.resmer.2023.101012_bib0003","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.annonc.2021.03.207","article-title":"Small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dingemans","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.resmer.2023.101012_bib0004","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/s41598-017-01571-0","article-title":"Survival changes in patients with small cell lung cancer and disparities between different sexes, socioeconomic statuses and ages","volume":"7","author":"Wang","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.resmer.2023.101012_bib0005","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resmer.2023.101012_bib0006","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1470-2045(20)30539-8","article-title":"Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial","volume":"22","author":"Goldman","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.resmer.2023.101012_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100408","article-title":"Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN","volume":"7","author":"Paz-Ares","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.resmer.2023.101012_bib0008","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-023568","article-title":"The ongoing French metastatic breast cancer (MBC) cohort: the example-based methodology of the epidemiological strategy and medical economics (ESME)","volume":"9","author":"Perol","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.resmer.2023.101012_bib0009","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.lungcan.2010.06.003","article-title":"Characteristics, treatment patterns and outcomes of patients with small cell lung cancer\u2014a retrospective single institution analysis","volume":"71","author":"Hermes","year":"2011","journal-title":"Lung Cancer"},{"key":"10.1016\/j.resmer.2023.101012_bib0010","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1111\/1759-7714.13977","article-title":"Survival and pretreatment prognostic factors for extensive-stage small cell lung cancer: a comprehensive analysis of 358 patients","volume":"12","author":"Huang","year":"2021","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.resmer.2023.101012_bib0011","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1080\/0284186X.2019.1711165","article-title":"Treatment patterns and survival outcomes for small-cell lung cancer patients \u2013 a Swedish single center cohort study","volume":"59","author":"Tendler","year":"2020","journal-title":"Acta Oncol"},{"key":"10.1016\/j.resmer.2023.101012_bib0012","doi-asserted-by":"crossref","first-page":"S214","DOI":"10.1016\/j.jtho.2019.08.424","article-title":"OA04.02 checkmate 817: first-line nivolumab\u00a0+\u00a0ipilimumab in patients with ECOG PS 2 and other special populations with advanced NSCLC","volume":"14","author":"Barlesi","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.resmer.2023.101012_bib0013","doi-asserted-by":"crossref","first-page":"e539","DOI":"10.1016\/j.cllc.2020.04.006","article-title":"The role of performance status in small-cell lung cancer in the era of immune checkpoint inhibitors","volume":"21","author":"Friedlaender","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.resmer.2023.101012_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.102894","article-title":"The use of radiation therapy for oligoprogressive\/oligopersistent oncogene-driven non small cell lung cancer: state of the art","volume":"148","author":"Franceschini","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.resmer.2023.101012_bib0015","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.lungcan.2017.03.007","article-title":"Which patients with ES-SCLC are most likely to benefit from more aggressive radiotherapy: a secondary analysis of the Phase III CREST trial","volume":"108","author":"Slotman","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.resmer.2023.101012_bib0016","series-title":"2021 Update of AURA guidelines for small-cell lung cancers","article-title":"On behalf of the editing committee of Auvergne Rh\u00f4ne\u2013Alpes guidelines in thoracic oncology","author":"Falchero","year":"2022"},{"key":"10.1016\/j.resmer.2023.101012_bib0017","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.7150\/jca.13080","article-title":"Second-line therapy of small-cell lung cancer: topotecan compared to a combination treatment with adriamycin, cyclophosphamide and vincristine (ACO) - a single centre experience","volume":"6","author":"Hagmann","year":"2015","journal-title":"J Cancer"},{"key":"10.1016\/j.resmer.2023.101012_bib0018","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/j.jtho.2018.05.037","article-title":"Development and validation of a nomogram prognostic model for SCLC patients","volume":"13","author":"Wang","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.resmer.2023.101012_bib0019","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/S1470-2045(20)30461-7","article-title":"Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial","volume":"21","author":"Baize","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.resmer.2023.101012_bib0020","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1470-2045(20)30068-1","article-title":"Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial","volume":"21","author":"Trigo","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.resmer.2023.101012_bib0021","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jtho.2020.01.016","article-title":"New approaches to SCLC therapy: from the laboratory to the clinic","volume":"15","author":"Poirier","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.resmer.2023.101012_bib0022","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1158\/1078-0432.CCR-20-2845","article-title":"AMG 757, a half-life extended, DLL3-targeted bispecific T-cell engager, shows high potency and sensitivity in preclinical models of small-cell lung cancer","volume":"27","author":"Giffin","year":"2021","journal-title":"Clin Cancer Res"}],"container-title":["Respiratory Medicine and Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590041223000247?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590041223000247?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T01:03:02Z","timestamp":1762909382000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590041223000247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":22,"alternative-id":["S2590041223000247"],"URL":"https:\/\/doi.org\/10.1016\/j.resmer.2023.101012","relation":{},"ISSN":["2590-0412"],"issn-type":[{"value":"2590-0412","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment patterns and clinical outcomes of extensive stage small cell lung cancer (SCLC) in the real-world evidence ESME cohort before the era of immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine and Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.resmer.2023.101012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 SPLF and Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101012"}}